Peran Jalur Phosphatidyl-Inositol-3-kinase (PI3K) dalam Resistensi Kemoterapi pada Kanker

Zanuar Abidin

Abstract

Cancer has the ability to develop resistance to chemotherapy and increased prevalence of this drug-resistant cancer requires further research and development of treatment. There are several mechanisms that can stimulate chemotherapy resistance, such as drug inactivation, drug effectiveness mechanism, HER2 role, PI3K pathway, DNA damage repair, and apoptotic inhibition. The PI3K pathway is an important signal transduction pathway in the growth and development of cancer. This pathway plays a role in several functions, such as proliferation, cell growth, and tumor survival. PI3K activation has been identified in some cases of cancer, including breast cancer. This pathway undergoes excessive activation resulting in resistance to chemotherapy and increased metastasis.

Keywords

PI3K, resistensi kemoterapi, kanker

References

DAFTAR PUSTAKA

Akinleye et. al., 2013. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. Journal of Hematology and Oncology., 6:88.

Arteaga CL, Sliwkowski MX, Osborne CK, et. al., 2011. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol., 9(1):16–32.

Brown, K.K. & Toker, A., 2015. The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Reports, 7. Available at: http://www.f1000.com/prime/reports/b/7/13.

Chrisanthar, Ranjan. 2008. Resistance to Chemotherapy in Breast Cancer : Potential Role of p21B,p27, and the p53 Apoptotic Pathway. Norway : Institute of Medicine and Department of Molecular Biology University of Bergen.

Fang J, Ding M, Yang L, Liu LZ, Jiang BH., 2007. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal.,19:2487-97.

Ghayad SE, Vendrell JA, Larbi SB, et. al., 2010. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer., 126 (2):545–62.

Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A et. al., 2008. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature, 453:662-6.

Gutierres JM, Carvalho FB, Schetinger MR, et. al., 2012. Protective effects of anthocyanins on the ectonucleotidase activity in the impairment of memory induced by scopolamine in adult rats. Life Sci, 91, 1221-8.

Hall MD, Handley MD, Gottesman MM., 2009. Is resistance useless? Multidrug resistance and collateral sensitivity. Trend Pharmacol Sci., 30 (10):546–56.

Hauptman et.al., 2013. MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiol Oncol., 47: 311-318.

Holohan, C.; van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G., 2013. Cancer drug resistance: An evolving paradigm. Nat. Rev., 13, 714–726.

Housman, G. et. al., 2014. Drug resistance in cancer: an overview. Cancers, 6(3), pp.1769–1792.

Kementrian Kesehatan Republik Indonesia. 2013. Riset Kesehatan Dasar Tahun 2013. Jakarta : Badan Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan RI.

Kementerian Kesehatan Republik Indonesia. 2015. Panduan Nasional Penanganan Kanker Payudara. Jakarta : Komite Nasional Penanggulangan Kanker Kementerian Kesehatan RI.

Kim D, Cheng GZ, Lindsley CW, Yang H, Cheng JQ., 2005. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr.Opin.Investig.Drugs, 6:1250-8.

Luo, L. et. al., 2014. Anti-metastasis Activity of Black Rice Anthocyanins Against Breast Cancer : Analyses Using an ErbB2 Positive Breast Cancer Cell Line and Tumoral Xenograft Model. Asian Pacific Journal of Cancer Prevention., 15, pp.6219–6225.

Maier, P.; Spier, I.; Laufs, S.; Veldwijk, M.R.; Fruehauf, S.; Wenz, F.; Zeller, W.J., 2010. Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase (P140K). Gene Ther., 17, 389–399.

Manning B, et.al.,2007. AKT/PKB signaling: navigating downstream. Cell, 129(7):1261–1274.

Marquette, C. & Nabell, L., 2012. Chemotherapy-Resistant Metastatic Breast Cancer. Current Treatment Options in Oncology, 13(2), pp.263–275.

McDonald, Gail Theresa. 2008. Thesis : Inhibition Phosphatidyl-Inositol-3-Kinase (PI3K) Signalling Leads to Resistance to Chemotherapeutic Agents in Human Cancer Cells. Ontario, Canada : Department of Anatomy and Cell Biology Queen’s University.

Press MF, Finn RS, Cameron D, et. al., 2008. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and Lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res, 14, 7861-70.

Schulz, Wolfgang Arthur. 2005. Molecular Biology of Human Cancers. Dusseldorf : Springer Science and Business Media Inc.

Sudiana, I Ketut. 2011. Patobiologi Molekuler Kanker. Jakarta : Salemba Empat.

Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM., 2006. Targeting multidrug resistance in cancer. Nat Rev Drug Discov., 5(3):219–34.

Tyagi, Manoj G, A Babu Vimalanathan and A Kanikkai Raja., 2009. The role of PI-3 kinase in cancer biology and approaches to the therapeutics of cancer. Biology and Medicine., 1;4(Rev)1.

Wong, R.S.Y., 2011. Apoptosis in cancer : from pathogenesis to treatment. Journal of Experimental & Clinical Cancer Research, 30(1), p.87.

World Health Organization.,2014. Cancer Country Profile 2014 : Indonesia. Departement of Chronic Disease and Health Promotion.

Zahreddine, H & Borden, K.L., 2013. Mechanisms and insights into drug resistance in cancer. Front. Pharmacol., 4, 28.


DOI: http://dx.doi.org/10.30651/qm.v2i01.545